Aarti Drugs (NSE:AARTIDRUGS, BOM:524348) has restored production for a "particular product" at its T-150 unit at Tarapur in Maharashtra, India, according to a filing to the stock exchanges on Saturday.
In August, the company received 'Conditional Restart Directions' for manufacturing activity from the Maharashtra Pollution Control Board, after which the company restored the manufacturing process in compliance with the Directorate of Industrial Safety and Health (DISH) recommendations.
The company said the stoppage of manufacturing of the product has no material impact on the financials and operations of the business.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。